This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Manganese preparations proposed for the treatment of various cutaneous diseases (pustular acne, acne vulgaris, furunculosis, psoriasis, acne rosacea and sycosis vulgaris), coccogenic infections in general and for favorable effect on blood formation have long been marketed by many pharmaceutic manufacturers. Manganese butyrate 1 per cent solution has been the most universal parenteral preparation marketed for use in the treatment of the pustular dermatoses and deep seated coccic infections. Two firms (Mallinckrodt Chemical Works and Swan-Myers & Co.) submitted such a preparation to the Council fifteen years ago, at which time consideration was postponed for lack of acceptable evidence of its therapeutic usefulness. In all this time there has not been received from either of these two firms, or from any other firm marketing manganese butyrate, the additional evidence required by the Council. Swan-Myers & Co. has now been absorbed by Abbott Laboratories, which markets the compound under the name Mangatrate.
MANGANESE COMPOUNDS FOR CUTANEOUS DISEASES, COCCOGENIC INFECTIONS AND BLOOD FORMATION NOT ACCEPTABLE FOR NEW AND NONOFFICIAL REMEDIES. JAMA. 1940;114(3):248–249. doi:10.1001/jama.1940.62810030008012a
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: